Unfavorable prognosis stage I–II Hodgkin’s disease: selected studies analyzing the appropriate radiation volume and dosage and the most effective chemotherapy.
| Trial . | Treatment Regimens . | # Pts. . | Outcome . | . | Reference . |
|---|---|---|---|---|---|
| Abbreviations: RT, radiation therapy; STLI (S), subtotal nodal irradiation (splenic irradiation); CS, clinical stage; IF, involved field; EF, extended field; FFP, freedom from progression; DFS, disease free survival; FFTF, freedom from treatment failure; RFS, relapse free survival. | |||||
| EORTC H6U 1982–88 | A: 3 MOPP + Mantle + 3 MOPP | 165 | FFS 77% | SV (10 y) 87% | 12 |
| B: 3 ABVD + Mantle + 3 ABVD | 151 | 88%P < .0001 | 87%P = .52 | ||
| EORTC H7U 1988–92 | A: 6 EBVP + IFRT (36 Gy) | 160 | EFS 68% | SV(6 y) 82% | 13 |
| B: 6 MOPP/ABV + IF RT | 156 | 90%P < .0001 | 89%P = .18 | ||
| SWOG/ ECOG #2496 | A: 6 ABVD + IFRT (36 Gy) to bulk (>5 cm) | Open | Open | ||
| B: 12 weeks Stanford V + IFRT to bulky sites | |||||
| GHSG HD8 1993–98 | A: 4 COPP/ABVD + EF RT (30 Gy) + Bulk (10 Gy) | 532 | FFTF 86% | SV (5 years) 91% | 14 |
| B: 4 COPP/ABVD + IF RT (30 Gy) + Bulk (10 Gy) | 532 | 84% NS | 92% NS | ||
| GHSG HD11 1998–2003 | A: 4 ABVD + IF RT (30Gy) | 264 | 24-month-FFTF= 90% | 15 | |
| B: 4 ABVD + IF RT (20 Gy) | 257 | 24-month survival= 97% | |||
| C: 4 BEACOPP + IF RT (30 Gy) | 262 | After 4 ABVD: FFTF= 89%, | |||
| D: 4 BEACOPP + IF RT (20 Gy) | 268 | SV= 98% After 4 BEACOPP baseline: FFTF= 91%, SV= 97% After 30 Gy: FFTF= 93%, SV= 98% After 20 Gy: FFTF= 91%, SV= 99% | |||
| GHSG HD14 | A: 4 ABVD + IF RT (30 Gy) | Started January 2003 | Open | ||
| B: 2 BEACOPP escalated + 2 ABVD + IF RT (30 Gy) | |||||
| EORTC/ GELA H8U 1993–98 | A: 6 MOPP/ABV + IF RT (36 Gy) | 335 | RFS 94 % | SV (4 years) 90% | 16 |
| B: 4 MOPP/ABV + IF RT (36 Gy) | 333 | 95 % | 95% | ||
| C: 4 MOPP/ABV + STLI | 327 | 96 % NS | 93% NS | ||
| EORTC H9U 1998- | A: 6 ABVD + IFRT (30 Gy) | 276 | FFP overall 90% | ||
| B: 4 ABVD + IFRT | 277 | ||||
| C: 4 BEACOPP + IFRT | 255 | ||||
| Trial . | Treatment Regimens . | # Pts. . | Outcome . | . | Reference . |
|---|---|---|---|---|---|
| Abbreviations: RT, radiation therapy; STLI (S), subtotal nodal irradiation (splenic irradiation); CS, clinical stage; IF, involved field; EF, extended field; FFP, freedom from progression; DFS, disease free survival; FFTF, freedom from treatment failure; RFS, relapse free survival. | |||||
| EORTC H6U 1982–88 | A: 3 MOPP + Mantle + 3 MOPP | 165 | FFS 77% | SV (10 y) 87% | 12 |
| B: 3 ABVD + Mantle + 3 ABVD | 151 | 88%P < .0001 | 87%P = .52 | ||
| EORTC H7U 1988–92 | A: 6 EBVP + IFRT (36 Gy) | 160 | EFS 68% | SV(6 y) 82% | 13 |
| B: 6 MOPP/ABV + IF RT | 156 | 90%P < .0001 | 89%P = .18 | ||
| SWOG/ ECOG #2496 | A: 6 ABVD + IFRT (36 Gy) to bulk (>5 cm) | Open | Open | ||
| B: 12 weeks Stanford V + IFRT to bulky sites | |||||
| GHSG HD8 1993–98 | A: 4 COPP/ABVD + EF RT (30 Gy) + Bulk (10 Gy) | 532 | FFTF 86% | SV (5 years) 91% | 14 |
| B: 4 COPP/ABVD + IF RT (30 Gy) + Bulk (10 Gy) | 532 | 84% NS | 92% NS | ||
| GHSG HD11 1998–2003 | A: 4 ABVD + IF RT (30Gy) | 264 | 24-month-FFTF= 90% | 15 | |
| B: 4 ABVD + IF RT (20 Gy) | 257 | 24-month survival= 97% | |||
| C: 4 BEACOPP + IF RT (30 Gy) | 262 | After 4 ABVD: FFTF= 89%, | |||
| D: 4 BEACOPP + IF RT (20 Gy) | 268 | SV= 98% After 4 BEACOPP baseline: FFTF= 91%, SV= 97% After 30 Gy: FFTF= 93%, SV= 98% After 20 Gy: FFTF= 91%, SV= 99% | |||
| GHSG HD14 | A: 4 ABVD + IF RT (30 Gy) | Started January 2003 | Open | ||
| B: 2 BEACOPP escalated + 2 ABVD + IF RT (30 Gy) | |||||
| EORTC/ GELA H8U 1993–98 | A: 6 MOPP/ABV + IF RT (36 Gy) | 335 | RFS 94 % | SV (4 years) 90% | 16 |
| B: 4 MOPP/ABV + IF RT (36 Gy) | 333 | 95 % | 95% | ||
| C: 4 MOPP/ABV + STLI | 327 | 96 % NS | 93% NS | ||
| EORTC H9U 1998- | A: 6 ABVD + IFRT (30 Gy) | 276 | FFP overall 90% | ||
| B: 4 ABVD + IFRT | 277 | ||||
| C: 4 BEACOPP + IFRT | 255 | ||||